Abstract
This chapter includes a comprehensive review of all drugs to treat tuberculosis. The WHO has classified these drugs in five groups, with drugs in Group 1 being the most effective, and less toxic and drugs in Group 5 being drugs with unproven efficacy or frequent side effects and/or toxicity. Each drug is discussed in detail, including its mechanisms of action, suggested doses and side and adverse effects, as well as the required clinical and laboratory monitoring for each drug. Recently added drugs bedaquiine and delamanid are also included in this review.
Keywords: Adverse effects, Antituberculosis drugs, Bedaquiline, Cycloserine, Delamanid, Dose, Effectiveness, Ethambutol, Ethionamide, Fluroquinolones, Injectables, Isoniazid, Laboratory, Linezolid, Monitoring, PAS, Pyrazinamide, Rifampin, Toxicity, WHO .
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Diabetes Reviews
Current Neurovascular Research
Current Respiratory Medicine Reviews
Current Pediatric Reviews
Infectious Disorders - Drug Targets
Current Stem Cell Research & Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current Alzheimer Research
Current Aging Science
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents